NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
| NCT ID | NCT06725550 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-08-25 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.
Eligibility Criteria
Inclusion Criteria: * Any gender * 14-17 (Adolescents) and 18-80 (Adults) years old * Right-handed * Either outpatient or inpatient or status changing between each other * Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months. * Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and/or other palliative treatment allowed, not required. * Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits. * Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupunc
Frequently Asked Questions
Who can join the NCT06725550 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 80 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06725550 currently recruiting?
Yes, NCT06725550 is actively recruiting participants. Visit ClinicalTrials.gov or contact Indiana University to inquire about joining.
Where is the NCT06725550 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT06725550 clinical trial?
NCT06725550 is sponsored by Indiana University. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.